Biocant - Technology Transfer Association

biocant.pt

BIOCANT Park is the first Portuguese venue entirely devoted to Biotechnology. Here, advanced Life Sciences knowledge and technology are developed and applied creating value in business initiatives. Through an audacious investment by the Municipality of Cantanhede and by the Center for Neuroscience and Cell Biology of Coimbra, and taking advantage of the last years’ national investment in Life Sciences, it was possible to set out an integrated development strategy to promote entrepreneurship and economic growth. The core of the Park is the R&D center – BIOCANT, Biotechnology Innovation Center – where specialized research teams use their built-up scientific competences to generate novel services and products. The scientific units of BIOCANT have committed staff and state-of-the-art equipment with high-throughput capacity.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Industrial Impact

ALDEVRON LAUNCHES TYPE-V CRISPR NUCLEASE, EURECA-V™ MAD7®

Aldevron | January 20, 2023

news image

Aldevron®, a worldwide leader in the custom development and production of plasmid DNA, RNA, and proteins for the biotech sector, recently announced the launch of Eureca-V™ nuclease. Eureca-V™, licensed from Inscripta®, is the wild-type MAD7® CRISPR Type-V nuclease at research grade, with GMP to follow. The launch of Aldevron's Eureca-V nuclease at advanced therapies week expands the toolkit of accessible CRISPR nucleases for therapeutic, di...

Read More

Medical

PFIZER INVESTS $120 MILLION IN FOUR CLINICAL-STAGE BIOTECH COMPANIES THROUGH THE PFIZER BREAKTHROUGH GROWTH INITIATIVE

Pfizer | January 15, 2021

news image

Pfizer Inc. declared that, during the second 50% of 2020, it put a sum of $120 million of every four clinical-stage biotech organizations as a feature of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is putting up to $500 million in biotechnology organizations, giving subsidizing and admittance to Pfizer's logical skill to help guarantee the coherence of promising clinical improvement projects of likely future vital interest to Pfizer. Pfizer's ini...

Read More

Industrial Impact

SIGA ANNOUNCES ONCOLOGY COLLABORATION WITH KALIVIR IMMUNOTHERAPEUTICS

SIGA Technologies Inc. | July 16, 2022

news image

SIGA Technologies, Inc. a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform. This novel oncolytic platform includes multiple proprietary genetic modifications that can be combined to generate a unique oncolytic virus that has been optimized for systemic delivery and anti-tumor immune stimulatio...

Read More

Diagnostics

CANCER CELL PAPER IDENTIFIES "AVIDITY ENHANCEMENT" AS NEW STRATEGY FOR IMPROVING CAR T THERAPY FOR ACUTE MYELOID LEUKEMIA

LUMICKS | May 26, 2022

news image

LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, today announced the publication in Cancer Cell of preclinical research identifying "Avidity Enhancement" as a new strategy to improve therapeutic outcome of Chimeric Antigen Receptor (CAR) T cell immunotherapy in Acute Myeloid Leukemia (AML). AML poses significant clinical challenges due to its resistance to therapies and its bleak prognosi...

Read More
news image

Cell and Gene Therapy, Industrial Impact

ALDEVRON LAUNCHES TYPE-V CRISPR NUCLEASE, EURECA-V™ MAD7®

Aldevron | January 20, 2023

Aldevron®, a worldwide leader in the custom development and production of plasmid DNA, RNA, and proteins for the biotech sector, recently announced the launch of Eureca-V™ nuclease. Eureca-V™, licensed from Inscripta®, is the wild-type MAD7® CRISPR Type-V nuclease at research grade, with GMP to follow. The launch of Aldevron's Eureca-V nuclease at advanced therapies week expands the toolkit of accessible CRISPR nucleases for therapeutic, di...

Read More
news image

Medical

PFIZER INVESTS $120 MILLION IN FOUR CLINICAL-STAGE BIOTECH COMPANIES THROUGH THE PFIZER BREAKTHROUGH GROWTH INITIATIVE

Pfizer | January 15, 2021

Pfizer Inc. declared that, during the second 50% of 2020, it put a sum of $120 million of every four clinical-stage biotech organizations as a feature of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is putting up to $500 million in biotechnology organizations, giving subsidizing and admittance to Pfizer's logical skill to help guarantee the coherence of promising clinical improvement projects of likely future vital interest to Pfizer. Pfizer's ini...

Read More
news image

Industrial Impact

SIGA ANNOUNCES ONCOLOGY COLLABORATION WITH KALIVIR IMMUNOTHERAPEUTICS

SIGA Technologies Inc. | July 16, 2022

SIGA Technologies, Inc. a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform. This novel oncolytic platform includes multiple proprietary genetic modifications that can be combined to generate a unique oncolytic virus that has been optimized for systemic delivery and anti-tumor immune stimulatio...

Read More
news image

Diagnostics

CANCER CELL PAPER IDENTIFIES "AVIDITY ENHANCEMENT" AS NEW STRATEGY FOR IMPROVING CAR T THERAPY FOR ACUTE MYELOID LEUKEMIA

LUMICKS | May 26, 2022

LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, today announced the publication in Cancer Cell of preclinical research identifying "Avidity Enhancement" as a new strategy to improve therapeutic outcome of Chimeric Antigen Receptor (CAR) T cell immunotherapy in Acute Myeloid Leukemia (AML). AML poses significant clinical challenges due to its resistance to therapies and its bleak prognosi...

Read More

Resources

resource image

Industry Outlook

A Playbook for Emerging Biotechs

Whitepaper

resource image

Cell and Gene Therapy, MedTech

Multi-Specific Monoclonal Antibodies

Whitepaper

resource image

Industry Outlook

A Playbook for Emerging Biotechs

Whitepaper

resource image

Cell and Gene Therapy, MedTech

Multi-Specific Monoclonal Antibodies

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us